Transgene S.A. Transgene S.A.

Transgene S.A.

TNG

Classement en actions #17533
Transgene SA, a French biotechnology firm headquartered in... Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
Prix de l'action
$0.81014398
Capitalisation boursière
$225.43M
Changement (1 jour)
0.15%
Changement (1 an)
-48.27%
Pays
FR
Échange Transgene S.A. (TNG)

Catégorie

Healthcare
Ratio P/B pour Transgene S.A. (TNG)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Transgene S.A., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Transgene S.A. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.251 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 13.2547 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 4.208 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.1824 -
NL